Press "Enter" to skip to content

MediciNov Sees Volume After Zacks Research Raises Price Target To $28

  • MediciNov Inc (NASDAQ: MNOV) sees a trading volume of 18.5 million shares after Zacks Small Cap Research increased the stock price target to $28 from $26.5 earlier.
  • The research notes positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) published in Translational Psychiatry.
  • While ibudilast did not significantly affect negative mood, it reduced the odds of heavy drinking across time by 45%, attenuated alcohol cue-elicited activation in the ventral striatum compared to placebo.
  • It also reduced alcohol craving compared to placebo on non-drinking days.
  • There were no significant differences between groups on any baseline characteristic, and overall medication compliance was high.
  • Price Action: During the mid-day session, the stock was trading 7.38% lower at $3.89 on the last check Tuesday.

Latest Ratings for MNOV

Date Firm Action From To
Mar 2021 Maxim Group Initiates Coverage On Buy
Mar 2020 B. Riley Securities Maintains Buy
Mar 2019 B. Riley Securities Assumes Buy

View More Analyst Ratings for MNOV

View the Latest Analyst Ratings

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *